The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

Background and Purpose—Evidence from the real-world setting complements evidence
coming from randomized controlled trials. We aimed to summarize all available evidence …

Background and Purpose—The use of oral anticoagulant therapy for stroke prevention in
atrial fibrillation has been transformed by the availability of the nonvitamin K antagonist oral …

Background and Purpose—This study was designed to evaluate the effectiveness and
safety of rivaroxaban in real-world practice compared with effectiveness and safety of …

Aims The aim of this study was to compare the risk of stroke or systemic embolism (SE) and
major bleeding in patients with atrial fibrillation (AF) using dabigatran, rivaroxaban, and …

Background and Purpose—Limited data are available describing the relative effectiveness,
safety, and optimal dosing of non–vitamin K antagonist oral anticoagulants (NOACs) for …

Background Comparative data of non‐vitamin K antagonist oral anticoagulants (NOAC) are
lacking in patients with atrial fibrillation (AF). Objective We compared effectiveness and …

Importance Current guidelines recommend direct oral anticoagulants (DOACs) over warfarin
for stroke prevention in patients with atrial fibrillation (AF) who are at high risk. Despite …

Background and Purpose: The effects of direct oral anticoagulants in nonvalvular atrial
fibrillation should be assessed in actual conditions of use. France has near-universal …

Self-terminating atrial arrhythmias are commonly detected on continuous rhythm monitoring,
eg by pacemakers or defibrillators. It is unclear whether the presence of these arrhythmias …